... Sometimes, targeted therapies such as those listed below, are used in combination with low-intensity chemotherapy to treat AML: Rydapt (Midostaurin) for AML cells with an FLT3 gene mutation Xospata (Gilteritinib) Venclexta (Venetoclax) Daurismo (Glasdegib) Other agents have recently been approved for specific AML cases: Mylotarg (Gemtuzumab ozogamicin ...
Acute Myeloid Leukemia Treatment Options
... Sometimes, targeted therapies such as those listed below, are used in combination with low-intensity chemotherapy to treat AML: Rydapt (Midostaurin) for AML cells with an FLT3 gene mutation Xospata (Gilteritinib) Venclexta (Venetoclax) Daurismo (Glasdegib) Other agents have recently been approved for specific AML cases: Mylotarg (Gemtuzumab ozogamicin ...
... Certain people with AML may also be able to take glasdegib (Daurismo). This targeted therapy drug can be used along with low doses of chemotherapy for people who are 75 years old or older, or for those who can’t use more aggressive chemotherapy because they have other health conditions.How Are Targeted Therapy Drugs Used? ...
The Benefits of Targeted Therapy for Leukemia
... Certain people with AML may also be able to take glasdegib (Daurismo). This targeted therapy drug can be used along with low doses of chemotherapy for people who are 75 years old or older, or for those who can’t use more aggressive chemotherapy because they have other health conditions.How Are Targeted Therapy Drugs Used? ...
... Other targeted therapies currently being studied in MDS include: Estybon (rigosertib) Imetelstat Pevonedistat Selinexor Daurismo (glasdegib) ImmunosuppressantsImmunosuppressants are medications that reduce the activity of the immune system. ...
What Is Myelodysplastic Syndrome (MDS)?
... Other targeted therapies currently being studied in MDS include: Estybon (rigosertib) Imetelstat Pevonedistat Selinexor Daurismo (glasdegib) ImmunosuppressantsImmunosuppressants are medications that reduce the activity of the immune system. ...